Needham & Company Reiterates Buy on Vascular Solutions (VASC) Following 3Q Report

October 25, 2016 8:32 AM EDT
Get Alerts VASC Hot Sheet
Price: $55.75 -0.18%

Rating Summary:
    1 Buy, 5 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 35 | Down: 31 | New: 11
Trade VASC Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Needham & Company reiterated a Buy rating and $58.00 price target on Vascular Solutions (NASDAQ: VASC) following the company's 3Q earnings report. Revenue was reported in-line with consensus at $41.8M. Adjusted EPS was $0.31 vs. consensus of $0.30. The EPS upside was driven by a lower than expected tax rate of 25.0%.

Analyst Mike Matson commented, "VASC's 3Q16 revenue met and EPS beat consensus. Guidance for 4Q16 revenue was slightly above consensus and guidance for 4Q16 EPS bracketed consensus. And the mid-points of VASC's initial 2017 revenue and EPS guidance were above consensus. Consistent with prior quarters, Turnpike, GuideLiner, and Micro-Introducer kits were biggest contributors to revenue growth. Operating margin was lower than expected due to mix, a vein catheter reprocessing pricing promotion, and the Twin-Pass recall but this was more than offset by a lower than expected tax rate. We expect upside to estimates and increased confidence in the RePlas opportunity to drive VASC shares higher and we reiterate our Buy rating."

For an analyst ratings summary and ratings history on Vascular Solutions click here. For more ratings news on Vascular Solutions click here.

Shares of Vascular Solutions closed at $48.63 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Needham & Company, Earnings

Add Your Comment